Home  >  News
Corporate + Font Resize -

Dr. Reddy’s gets US FDA approval for Impoyz cream, 0.025%

Our Bureau, Mumbai
Friday, December 1, 2017, 12:15 Hrs  [IST]

Dr. Reddy’s Laboratories, through its wholly owned subsidiary Promius Pharma, LLC, has received its fifth consecutive, first-cycle NDA approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry.

Impoyz (clobetasol propionate) cream, 0.025% is a high potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. The most common side effect of Impoyz cream includes discoloration of the treated site. Psoriasis is a serious medical condition affecting approximately 7.5 million people in the United States. Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc. for the commercialization of the product in the United States.

This approval is another example of the deep and broad capabilities within the Proprietary Products business unit at Dr Reddy’s. The organization has achieved several milestones within drug, device, and formulation research and development for novel therapies.

“The fifth consecutive first cycle NDA approval represents Dr Reddy’s long-term commitment to building an organization that delivers innovative medical solutions,” said Anil Namboodiripad, PhD, senior vice president, Proprietary Products and president, Promius Pharma. “We are looking forward to working with our partner, Encore Dermatology, to bring this novel treatment to providers and their patients.”

“Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialize a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne,” said Robert Moccia, chief executive officer, Encore Dermatology.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |